Exhibit 99.1

USANA Expects Earnings to Significantly Exceed Earlier Guidance; Sales
In-line with Prior Forecast

    SALT LAKE CITY--(BUSINESS WIRE)--Sept. 23, 2003--USANA Health
Sciences Inc. (NASDAQ: USNA) announced today that it now expects
earnings per share for the third quarter to exceed the company's
earlier guidance and looks for sales to be in-line with its prior
forecast.
    The company continues to expect that sales for the quarter ending
Sept. 27, 2003 will approach $52 million. However, earnings per share
are expected to be approximately $0.54, of which about $0.03 would be
attributable to an adjustment of the company's effective tax rate for
2003. Initial guidance for the third quarter had earnings per share in
the range of $0.43 to $0.45.
    Gilbert A. Fuller, chief financial officer, commented, "We are
pleased with the strong earnings and sales growth we are experiencing
this quarter. We continue to see operating margin improvements as we
leverage the physical and information technology infrastructure
investments made over the last several years. Earnings per share and
sales for the quarter are expected to be up approximately 145% and
48%, respectively, on a year-over-year basis. The third quarter of
2003 will represent the seventh consecutive quarter in which we have
more than doubled the prior year EPS mark."
    USANA plans to announce its third quarter earnings along with new
guidance for the fourth quarter and for the fiscal year 2004, on Oct.
14, 2003; executives will hold a conference call with investors on
Oct. 15, 2003, to provide an update.
    USANA develops and manufactures high-quality nutritionals,
personal care, and weight management products that are sold directly
to Preferred Customers and Associates throughout the United States,
Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea
and the United Kingdom. More information on USANA can be found at
http://www.usanahealthsciences.com.

    This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. Actual results could differ materially from
those projected in the forward-looking statements, which involve a
number of risks and uncertainties, including reliance upon the
company's independent Associate network, government regulation of
products, manufacturing and marketing, the possible continued spread
of severe acute respiratory syndrome (SARS) in Asia, and risks
associated with international expansion. Those statements include the
statements that (1) "The company continues to expect that sales for
the quarter ending Sept. 27, 2003 will approach $52 million," (2)
"earnings per share are expected to be approximately $0.54," (3)
"about $0.03 would be attributable to an adjustment of the company's
effective tax rate for 2003," and (4) "Earnings per share and sales
for the quarter are expected to be up approximately 145% and 48%,
respectively, on a year-over-year basis." The contents of this release
should be considered in conjunction with the warnings and cautionary
statements contained in USANA's most recent filings with the
Securities and Exchange Commission on Forms 10-Q and 10-K.

    CONTACT: USANA Health Sciences Inc., Salt Lake City
             Riley Timmer, 801-954-7100
             investor.relations@us.usana.com